Hill-Rom (NYSE:HRC) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided EPS guidance of $0.77-0.79 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.79. The company issued revenue guidance of $670 million, compared to the consensus revenue estimate of $656.42 million.
Shares of Hill-Rom (NYSE:HRC) opened at $86.79 on Tuesday. Hill-Rom has a one year low of $57.18 and a one year high of $88.91. The stock has a market capitalization of $5,710.00, a price-to-earnings ratio of 43.61, a price-to-earnings-growth ratio of 1.55 and a beta of 1.19. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.34 and a current ratio of 1.77.
Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.27 by $0.05. Hill-Rom had a return on equity of 20.27% and a net margin of 4.87%. The business had revenue of $738.30 million during the quarter, compared to analyst estimates of $731.10 million. During the same period last year, the business posted $1.18 earnings per share. The company’s quarterly revenue was up 4.6% on a year-over-year basis. equities analysts expect that Hill-Rom will post 4.32 EPS for the current year.
A number of research firms recently issued reports on HRC. Barclays reiterated a buy rating and issued a $100.00 target price on shares of Hill-Rom in a report on Wednesday, January 10th. Zacks Investment Research lowered Hill-Rom from a buy rating to a hold rating in a report on Monday. Needham & Company LLC reaffirmed a buy rating and set a $105.00 price target on shares of Hill-Rom in a report on Tuesday. ValuEngine downgraded Hill-Rom from a buy rating to a hold rating in a report on Saturday, November 4th. Finally, Stifel Nicolaus lifted their price target on Hill-Rom from $84.00 to $85.00 and gave the stock a buy rating in a report on Monday, November 6th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of Hold and an average target price of $94.88.
In related news, SVP Paul Sherwood Johnson sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $82.99, for a total value of $82,990.00. Following the transaction, the senior vice president now owns 1,066 shares in the company, valued at approximately $88,467.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John J. Greisch sold 125,241 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $82.59, for a total value of $10,343,654.19. Following the completion of the transaction, the chief executive officer now owns 280,851 shares in the company, valued at approximately $23,195,484.09. The disclosure for this sale can be found here. Insiders have sold 226,241 shares of company stock worth $18,708,644 in the last quarter. Insiders own 2.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/hill-rom-hrc-updates-q1-earnings-guidance/1820391.html.
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.